Cargando…

Galectin-3 inhibition as a potential therapeutic target in non-alcoholic steatohepatitis liver fibrosis

Nonalcoholic fatty liver disease continues to be one of the major health challenges facing the world, with estimates of non-alcoholic steatohepatitis (NASH) prevalence in over 25 percent of the world’s population. NASH represents a spectrum of disease that may lead to hepatic fibrosis and eventual c...

Descripción completa

Detalles Bibliográficos
Autor principal: Kram, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011901/
https://www.ncbi.nlm.nih.gov/pubmed/36926236
http://dx.doi.org/10.4254/wjh.v15.i2.201

Ejemplares similares